We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Last Monday (24 February) the US biotech company VaxGen released the results of the first-ever, real-world test of an AIDS vaccine (see Mixed results for AIDS vaccine trial).

In this article Jon Cohen probes into the background to the announcement, and describes some of the reactions from the scientific community to its claims that the small subgroup of black, Asian and mixed-race participants were strongly protected by the vaccine.

It seems likely that VaxGen's analyses have touched off a debate that promises to reverberate around the community for weeks, if not months, to come.

Link to full Science article

Reference: Science 299, 1290 (2003)

Related topics